Liver and Metabolic Effects of Insulin Pump Therapy in Diabetics Type 2 with Non-alcoholic Hepatic Steatosis

Exclusion Criteria

• •Type 1 diabetes
• •Contraindication to pump treatment
• •Treatment with anti-diabetics or other than metformin, dipeptidyl peptidase-4 (DPP4) and/or sodium-glucose cotransporter type 2 (SGLT2)
• •Treatment with basal inulin of Levemir
• •Contraindication to performing MRI
• •Chronic alcohol abuse (after alcohol consumption\> 20g / day in men and\> 10g / day in women) according to the medical examination
• •Chronic viral hepatitis based on HBV and HCV serology results
• •Hemochromatosis according to the martial assessment
• •Other toxic or drug hepatitis
• •Severe hepatic pathology: hepatic cirrhosis, hepatocellular carcinoma
• •Severe renal insufficiency (MDRD \<30 ml / min)
• •Severe and progressive cardiovascular pathology
• •Treatment (permanent or intermittent) with glucocorticoids
• •Treatment known to improve hepatic steatosis (glitazone, vitamin E, orlistat)
• •history or bariatric surgery project for the duration of the study
• •Drug treatment likely to cause hepatic steatosis (amiodarone, carbamazepine, tamoxifen, valproate, clozapine, anti-retroviral drugs) unless the dose has been stable for ≥ 3 months
• •Guardianship, curatorship or safeguard of justice